Antihypertensive therapy reduces increased plasma levels of adrenomedullin and brain natriuretic peptide concomitant with regression of left ventricular hypertrophy in a patient with malignant hypertension

Hypertension Research

Volumn 19, Issue 2, 1996, Pages 97-101

  Nishikimi, Toshio ^a   Matsuoka, Hiroaki ^a   Ishikawa, Kazuhiko ^a   Yoshihara, Fumiki ^a   Kawano, Yuhei ^a   Kitamura, Kazuo ^b   Saito, Yoshihiko ^a   Kangawa, Kenji ^a   Matsuo, Hisayuki ^a   Omae, Teruo ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Adrenomedullin; Blood pressure; Brain natriuretic peptide; Left ventricular hypertrophy; Malignant hypertension

Indexed keywords

ADRENOMEDULLIN; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; NICARDIPINE; NIFEDIPINE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE REGULATION; CASE REPORT; DEFENSE MECHANISM; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MALIGNANT HYPERTENSION; ORAL DRUG ADMINISTRATION; PAPILLEDEMA; RETINA HEMORRHAGE; VISUAL DISORDER;

ADRENOMEDULLIN; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; BLOOD PRESSURE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ENALAPRIL; HUMANS; HYPERTENSION, MALIGNANT; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NICARDIPINE; PEPTIDES; VISION DISORDERS;

EID: 0030035843     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.19.97     Document Type: Article

References (16)

1. Kitamura K, Kangawa K, Kawamoto M, et al: Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993; 192: 553-560.
2. Kitamura K, Sakata J, Kangawa K, Kojima M, Matsuo H, Eto T: Cloning and characterization of cDNA encoding a precursor for human adrenomedullin. Biochem Biophys Res Commun 1993; 194: 720-725.
3. Sugo S, Minamino N, Shoji H, et al: Production and secretion of adrenomedullin from vascular smooth muscle cells: augmented production by tumor necrosis factor-α. Biochem Biophys Res Commun 1994; 203: 719-726.
4. Eguchi S, Hirata Y, Kano H, et al: Specific receptors for adrenomedullin in cultured rat vascular smooth muscle cells. FEBS Lett 1994; 340: 226-230.
5. Ishimitsu T, Nishikimi T, Saito Y, et al: Plasma levels of adrenomedullin, a hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1994; 94: 2158-2161.
6. Nishikimi T, Saito Y, Kitamura K, et al: Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol 1995; 26: 1424-1431.
7. Kitamura K, Ichiki Y, Tanaka M, et al: Immunoreactive adrenomedullin in human plasma. FEBS Lett 1994; 341: 288-290.
8. Nishikimi T, Kitamura K, Saito Y, et al: Clinical studies for the sites of production and clearance of circulating adrenomedullin in human subjects. Hypertension 1994; 24: 600-604.
9. Minamino N, Sugo S, Shoji H, Kangawa K, Matsuo H: Adrenocortical steroids, thyroid hormones and retinoic acid augment the production of adrenomedullin in vascular smooth muscle cells. Biochem Biophys Res Commun 1995; 211: 686-693.
10. Shoji H, Minamino N, Sugo S, Kangawa K, Matsuo H: Effects of vasoactive substances and cyclic AMP related compounds on adrenomedullin production in cultured vascular smooth muscle cells. FEBS Lett 1995; 369: 311-314.
11. Shapiro LM, Beevers DG: Malignant hypertension: cardiac structure and function at presentation and during therapy. Br Heart J 1983; 49: 477-484.
12. Aristizabel D, Messerli FH, Frohlich ED: Disparate structural effects on left and right ventricles by angiotensin-converting enzyme inhibitors and calcium antagonist in essential hypertension. Am J Cardiol 1994; 73: 483-487.
13. Dahlöf B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients: a meta analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
14. Yasue H, Yoshimura M, Shimada H, et al: Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203.
15. Kohno M, Horio T, Yokokawa K, et al: Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992; 92: 29-34.
16. Nishikimi T, Yoshihara F, Morimoto A, et al: Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertens 1996 (in press).